Persistent low-back pain — where anti-inflammatory and neuropathic-pain compounds are explored alongside the mainstays.
Chronic low-back pain is multifactorial — disc, joint, muscle, and nerve contributions — which makes any single compound a long shot. Interest spans tissue repair (BPC-157), broad anti-inflammation, and neuropathic-pain modulation (low-dose naltrexone, ARA-290) where a nerve component is suspected.
None of this substitutes for a proper diagnosis. Evidence for these compounds in back pain specifically is minimal; movement, strengthening, and addressing the underlying driver are the proven path, with these as experimental adjuncts.
Ranked by editorial relevance — a measure of how central each compound is to the conversation, not a claim of effectiveness.
| Compound | Type | Why it's relevant |
|---|---|---|
| BPC-157 | peptide | Tissue-repair angle where structural. |
| Naltrexone | supplement | Low-dose; explored for chronic pain modulation. |
| Ara 290 | peptide | Tissue-protective; neuropathic-pain interest. |